4.11
-0.26(-5.95%)
Currency In USD
| Previous Close | 4.37 |
| Open | 4.3 |
| Day High | 4.5 |
| Day Low | 4.1 |
| 52-Week High | 22.32 |
| 52-Week Low | 3.81 |
| Volume | 7,433 |
| Average Volume | 18,337 |
| Market Cap | 36.55M |
| PE | 25.69 |
| EPS | 0.16 |
| Moving Average 50 Days | 4.74 |
| Moving Average 200 Days | 6.73 |
| Change | -0.26 |
If you invested $1000 in Serina Therapeutics Inc (SER) since IPO date, it would be worth $42.46 as of March 14, 2025 at a share price of $4.11. Whereas If you bought $1000 worth of Serina Therapeutics Inc (SER) shares 5 years ago, it would be worth $118.75 as of March 14, 2025 at a share price of $4.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
GlobeNewswire Inc.
Feb 12, 2025 9:15 PM GMT
HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointme
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
GlobeNewswire Inc.
Feb 03, 2025 9:30 PM GMT
HUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced the successful closing of the second $5 million tranche of its previously announced $10
Serina Therapeutics Announces Sale of UniverXome Subsidiary
GlobeNewswire Inc.
Jan 15, 2025 9:05 PM GMT
- Transaction eliminates $11.2 million in debt, strengthening financial position - HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its pro